DB:OB3

Stock Analysis Report

Executive Summary

Optibiotix Health Plc, a life sciences company, engages in the research and development of microbiome modulators primarily in the United Kingdom.


Snowflake Analysis

Mediocre balance sheet with weak fundamentals.

Share Price & News

How has OptiBiotix Health's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: OB3's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-11.0%

OB3

8.1%

DE Biotechs

7.2%

DE Market


1 Year Return

-64.4%

OB3

-5.4%

DE Biotechs

-17.5%

DE Market

Return vs Industry: OB3 underperformed the German Biotechs industry which returned -1.2% over the past year.

Return vs Market: OB3 underperformed the German Market which returned -14.1% over the past year.


Shareholder returns

OB3IndustryMarket
7 Day-11.0%8.1%7.2%
30 Day-45.6%-11.8%-22.3%
90 Day-56.9%-22.7%-26.1%
1 Year-64.4%-64.4%-5.2%-5.4%-14.9%-17.5%
3 Yearn/a17.6%16.3%-18.7%-25.7%
5 Yearn/a-5.1%-7.5%-17.8%-29.1%

Price Volatility Vs. Market

How volatile is OptiBiotix Health's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is OptiBiotix Health undervalued compared to its fair value and its price relative to the market?

4.32x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate OB3's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate OB3's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: OB3 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: OB3 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OB3's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OB3 is overvalued based on its PB Ratio (4.3x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is OptiBiotix Health forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

58.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as OptiBiotix Health has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has OptiBiotix Health performed over the past 5 years?

-8.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OB3 is currently unprofitable.

Growing Profit Margin: OB3 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OB3 is unprofitable, and losses have increased over the past 5 years at a rate of -8% per year.

Accelerating Growth: Unable to compare OB3's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OB3 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: OB3 has a negative Return on Equity (-33.37%), as it is currently unprofitable.


Next Steps

Financial Health

How is OptiBiotix Health's financial position?


Financial Position Analysis

Short Term Liabilities: OB3's short term assets (£1.4M) exceed its short term liabilities (£188.6K).

Long Term Liabilities: OB3's short term assets (£1.4M) exceed its long term liabilities (£1.2M).


Debt to Equity History and Analysis

Debt Level: OB3's debt to equity ratio (11.2%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if OB3's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: OB3 has a low level of unsold assets or inventory.

Debt Coverage by Assets: OB3's debt is covered by short term assets (assets are 2.1x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if OB3 has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if OB3 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is OptiBiotix Health's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OB3's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate OB3's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OB3's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OB3's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OB3's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average board tenure


CEO

Stephen O'Hara

no data

Tenure

UK£212,897

Compensation

Mr. Stephen Patrick O'Hara Founded OptiBiotix Health plc in March 2012 and serves as its Chief Executive. He also serves as the Board Director of ProBiotix Health Limited. Mr. O'Hara served as the Chief Ex ...


CEO Compensation Analysis

Compensation vs Market: Stephen's total compensation ($USD264.26K) is below average for companies of similar size in the German market ($USD429.96K).

Compensation vs Earnings: Stephen's compensation has increased whilst the company is unprofitable.


Board Members

NamePositionTenureCompensationOwnership
Stephen O'Hara
Founderno dataUK£212.90k11.82% £3.4m
Sofia Kolida
Director of Research & Development and Executive Director1.67yrsUK£108.33kno data
Frederic Narbel
Executive Director & Managing Director of Prebiotics Division1yrno data0.064% £18.7k
Sean Christie
Non-Executive Director1.5yrsUK£7.79k0.15% £42.7k
Tim Spector
Member of Scientific Advisory Group4.17yrsno datano data
Neil Davidson
Non-Executive Chairman2.17yrsUK£57.85k0.56% £163.2k
Jan Peter Wennström
Non-Executive Director4.33yrsUK£18.00kno data

2.2yrs

Average Tenure

61.5yo

Average Age

Experienced Board: OB3's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.9%.


Top Shareholders

Company Information

OptiBiotix Health Plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: OptiBiotix Health Plc
  • Ticker: OB3
  • Exchange: DB
  • Founded: 2012
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£26.059m
  • Listing Market Cap: UK£29.173m
  • Shares outstanding: 85.44m
  • Website: https://www.optibiotix.com

Number of Employees


Location

  • OptiBiotix Health Plc
  • Innovation Centre
  • Innovation Way
  • York
  • North Yorkshire
  • YO10 5DG
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OPTIAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPAug 2014
OPBX.FOTCPK (Pink Sheets LLC)SHSUSUSDOct 2015
OPTIAIM (London Stock Exchange AIM Market)ORD GBP0.02GBGBPNov 2016
OB3DB (Deutsche Boerse AG)ORD GBP0.02DEEURNov 2016

Biography

Optibiotix Health Plc, a life sciences company, engages in the research and development of microbiome modulators primarily in the United Kingdom. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that impacts human physiology deriving potential health benefits. Its products include Slimbiome, a natural ingredient, which offers a healthy and hunger-free weight management system; CholBiome, an ingredient for use in a range of functional food products and supplements in consumer and pharmaceutical health care; Lactobacillus plantarum LPLDL, a probiotic that aids elements of cardiovascular and wellbeing; LPGOS, a galacto oligosaccharide that are used in food products and applications, which helps in reducing cardiovascular risk factors and enhancing health; and Sweetbiotix, a sweetener for use in food products and beverages. The company’s products prevents and manages chronic lifestyle diseases, including obesity, hypercholesterolemia and lipid profiles, and diabetes. Optibiotix Health Plc was founded in 2012 and is headquartered in York, the United Kingdom. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/27 23:56
End of Day Share Price2020/03/27 00:00
Earnings2019/05/31
Annual Earnings2018/11/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.